# CARTITUDE-5 (NCT04923893)

> A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04923893
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Bortezomib; Dexamethasone; Lenalidomide; Cilta-cel; Cyclophosphamide; Fludarabine
- Enrollment: 743
- Primary outcome: Progression Free Survival (PFS)

## Commentary we found

- YouTube: 42
- X threads: 31
- Podcasts: 15

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cartitude-5-nct04923893

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04923893", "email": "<work email>"}; the inbox owner confirms by the emailed link.